BMO Capital Reiterates Outperform Rating on Protagonist Therapeutics (PTGX)

May 11, 2026 9:22 AM

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $112.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found